Literature DB >> 7679748

Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

R Gavioli1, M G Kurilla, P O de Campos-Lima, L E Wallace, R Dolcetti, R J Murray, A B Rickinson, M G Masucci.   

Abstract

Epstein-Barr virus (EBV), a ubiquitous herpesvirus, induces potent HLA class I-restricted cytotoxic T-lymphocyte (CTL) responses. Analyses of target antigen choice have shown that the very strong CTL responses which are often observed through the HLA A11 allele map are due almost entirely to a single transformation-associated EBV protein, the nuclear antigen EBNA4. Here, we sought to determine the number and relative immunogenicities of HLA A11-restricted epitopes within this 938-amino-acid protein. An initial screening with a series of recombinant vaccinia virus vectors encoding progressively truncated forms of EBNA4 was followed by peptide sensitization experiments using overlapping 14- or 15-mers from the entire sequence. These two approaches allowed the identification of five epitope regions located between residues 101 and 115, 416 and 429, 396 and 410, 481 and 495, and 551 and 564 of the EBNA4 molecule. CTL preparations from all seven HLA A11-positive donors tested had demonstrable reactivities against the 416-to-429 peptide, whereas reactivities against the other epitopes either tended to be lost on serial passage or, for some of the donors, were never detected. The immunodominance of the 416-to-429 epitope was further supported by peptide dilution assays using polyclonal effectors and by CTL cloning experiments. Analysis of the 416-to-429 region identified the nanomer 416-424 (IVTDFSVIK) as the cognate peptide. This peptide was able to sensitize targets to lysis by A11-restricted CTL clones at concentrations as low as 5 x 10(-14) M.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679748      PMCID: PMC237528     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Standards for total serum protein assays--a collaborative study.

Authors:  B T Doumas
Journal:  Clin Chem       Date:  1975-07       Impact factor: 8.327

2.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.

Authors:  C Schmidt; S R Burrows; T B Sculley; D J Moss; I S Misko
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

Review 5.  The synthesis of peptides by homogeneous solution procedures.

Authors:  P G Katsoyannis; G P Schwartz
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

6.  Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen.

Authors:  L E Wallace; A B Rickinson; M Rowe; M A Epstein
Journal:  Nature       Date:  1982-06-03       Impact factor: 49.962

7.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

8.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2.

Authors:  L E Wallace; M Rowe; J S Gaston; A B Rickinson; M A Epstein
Journal:  Eur J Immunol       Date:  1982-12       Impact factor: 5.532

9.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

10.  Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line.

Authors:  A B Rickinson; D J Moss; D J Allen; L E Wallace; M Rowe; M A Epstein
Journal:  Int J Cancer       Date:  1981-05-15       Impact factor: 7.396

View more
  47 in total

1.  The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

Authors:  F Micheletti; M Bazzaro; A Canella; M Marastoni; S Traniello; R Gavioli
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes.

Authors:  R S Midgley; A I Bell; D J McGeoch; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Structure of HLA-A*1101 in complex with a hepatitis B peptide homologue.

Authors:  Thomas Blicher; Jette Sandholm Kastrup; Lars Østergaard Pedersen; Søren Buus; Michael Gajhede
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-04

4.  The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Authors:  Diego Marescotti; Federica Destro; Anna Baldisserotto; Mauro Marastoni; Giuseppe Coppotelli; Maria Masucci; Riccardo Gavioli
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

6.  The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression.

Authors:  D M Walling; A G Perkins; J Webster-Cyriaque; L Resnick; N Raab-Traub
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Authors:  R S Midgley; A I Bell; Q Y Yao; D Croom-Carter; A D Hislop; B M Whitney; A T C Chan; P J Johnson; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

9.  A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors:  S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution.

Authors:  J M Burrows; S R Burrows; L M Poulsen; T B Sculley; D J Moss; R Khanna
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.